Xencor, Inc.

Xencor, Inc.verified

XNCR

Price:

$25.01

Market Cap:

$1.75B

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat m...[Read more]

Industry

Biotechnology

IPO Date

2013-12-03

Stock Exchange

NASDAQ

Ticker

XNCR

The PE Ratio as of November 2024 (TTM) for Xencor, Inc. (XNCR) is -7.86

According to Xencor, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.86. This represents a change of -5.91% compared to the average of -8.35 of the last 4 quarters.

Xencor, Inc. (XNCR) Historical PE Ratio (quarterly & annually)

How has XNCR PE Ratio performed in the past?

The mean historical PE Ratio of Xencor, Inc. over the last ten years is -4.26. The current -7.86 PE Ratio has changed 18.34% with respect to the historical average. Over the past ten years (40 quarters), XNCR's PE Ratio was at its highest in in the September 2018 quarter at 171.34. The PE Ratio was at its lowest in in the March 2021 quarter at -251.04.

Quarterly (TTM)
Annual

Average

-4.26

Median

-24.29

Minimum

-39.29

Maximum

72.34

Xencor, Inc. (XNCR) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Xencor, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 544.69%

Maximum Annual PE Ratio = 72.34

Minimum Annual Increase = -362.07%

Minimum Annual PE Ratio = -39.29

Quarterly (TTM)
Annual
YearPE RatioChange
2023-10.19-63.81%
2022-28.15-199.31%
202128.35-172.15%
2020-39.29-154.31%
201972.34-362.07%
2018-27.6031.59%
2017-20.98-145.62%
201645.97-241.79%
2015-32.425.75%
2014-30.66544.69%

Xencor, Inc. (XNCR) Average PE Ratio

How has XNCR PE Ratio performed in the past?

The current PE Ratio of Xencor, Inc. (XNCR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-3.33

5-year avg

4.61

10-year avg

-4.26

Xencor, Inc. (XNCR) PE Ratio vs. Peers

How is XNCR’s PE Ratio compared to its peers?

Xencor, Inc.’s PE Ratio is greater than Edgewise Therapeutics, Inc. (-24.30), greater than Keros Therapeutics, Inc. (-11.12), less than Monte Rosa Therapeutics, Inc. (-5.83), less than Mineralys Therapeutics, Inc. (-4.06), less than Erasca, Inc. (-4.79), less than Kura Oncology, Inc. (-4.75), less than Protagonist Therapeutics, Inc. (16.80), greater than Merus N.V. (-12.70), less than Replimune Group, Inc. (-5.51), greater than Cerevel Therapeutics Holdings, Inc. (-17.73), greater than IDEAYA Biosciences, Inc. (-12.96), less than AnaptysBio, Inc. (-3.88), less than MeiraGTx Holdings plc (-4.82), less than Homology Medicines, Inc. (-0.01), greater than Nuvalent, Inc. (-27.80), greater than DICE Therapeutics, Inc. (-22.94), greater than Arcellx, Inc. (-120.42), greater than Vaxcyte, Inc. (-21.57), less than Viridian Therapeutics, Inc. (-5.22), less than Larimar Therapeutics, Inc. (-6.07), less than Syndax Pharmaceuticals, Inc. (-4.63), less than Sutro Biopharma, Inc. (-1.66),

Build a custom stock screener for Xencor, Inc. (XNCR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xencor, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xencor, Inc. (XNCR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xencor, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Xencor, Inc.'s PE Ratio?

How is the PE Ratio calculated for Xencor, Inc. (XNCR)?

What is the highest PE Ratio for Xencor, Inc. (XNCR)?

What is the 3-year average PE Ratio for Xencor, Inc. (XNCR)?

What is the 5-year average PE Ratio for Xencor, Inc. (XNCR)?

How does the current PE Ratio for Xencor, Inc. (XNCR) compare to its historical average?